Delfin Santos, MD
Rheumatology · Rochester, MINPI 1063420628
Payments from drug & device makers
Across 928 payments — averaging $261.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bristol Myers Squibb$119K
- Amgen$77K
- AbbVie$30K
- Pfizer$8K
- Johnson & Johnson$3K
- UCB, Inc.$2K
- plus $3K from 24 others
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Bristol Myers Squibb | 111 | $119,222 |
| Amgen(2 entities) | 211 | $76,738 |
| AbbVie | 112 | $29,853 |
| Pfizer | 105 | $7,927 |
| Johnson & Johnson | 129 | $2,898 |
| UCB, Inc. | 57 | $2,394 |
| E.r. Squibb & Sons, L.L.C. | 90 | $1,033 |
| Novartis | 28 | $501 |
| Genentech USA, Inc. | 20 | $257 |
| Lilly USA, LLC | 12 | $223 |
| Sanofi | 2 | $169 |
| AstraZeneca(2 entities) | 10 | $162 |
| Boehringer Ingelheim | 5 | $136 |
| GSK | 7 | $105 |
| Regeneron Healthcare Solutions, Inc. | 6 | $103 |
| Pacira Therapeutics, Inc. | 2 | $102 |
| Mallinckrodt Hospital Products Inc. | 3 | $59 |
| Sandoz | 2 | $55 |
| ANI Pharmaceuticals, Inc. | 2 | $45 |
| Sobi, Inc | 2 | $39 |
| Hikma Pharmaceuticals USA | 3 | $34 |
| Organon | 1 | $27 |
| Actelion Pharmaceuticals US, Inc. | 1 | $26 |
| Janssen Scientific Affairs, LLC | 1 | $26 |
| Aurinia Pharma U.S., Inc. | 1 | $20 |
| Sanofi-aventis U.S. LLC | 1 | $17 |
| Ultragenyx Pharmaceutical Inc. | 1 | $13 |
| Sebela Pharmaceuticals Inc. | 1 | $12 |
| Novo Nordisk | 1 | $12 |
| Biogen | 1 | $12 |
How this compares
$242,220 in reported general payments places this provider in the 90th percentile of 195 rheumatology providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other rheumatology in Rochester
- Dinesh KhannaAnn Arbor$28M
- Amar MajjhooSaint Clair Shores$9.1M
- Joanne KahlenbergAnn Arbor$6M
- Andrew SulichSaint Clair Shores$3.4M
- Elena SchiopuAnn Arbor$3M
- Ali KarrarGrand Blanc$2.5M
- Joshua JuneLansing$2.3M
- Monika MohanOkemos$1.6M
- Kathleen Maksimowicz McKinnonDetroit$842K
- Roman CzubatyjRochester Hills$764K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.